streptococcu
pneumonia
isol
caus
ipd
januari
june
collect
cmcd
microbiolog
laboratori
method
describ
previou
report
invas
pneumococc
diseas
case
defin
isol
pneumonia
normal
steril
site
eg
blood
pleural
fluid
cerebrospin
fluid
join
fluid
evid
chest
radiograph
infiltr
isol
bacteria
least
follow
site
confirm
diagnosi
pneumococc
pneumonia
blood
pleural
fluid
empyema
case
pneumonia
present
bacteremia
clinic
syndrom
divid
isol
pneumonia
bacterem
pneumonia
isol
bacteremia
medic
record
patient
cultureconfirm
ipd
cmcd
review
demograph
clinic
data
extract
subject
recurr
ipd
multipl
serotyp
isol
includ
analysi
patient
inform
obtain
accord
health
inform
protect
portabl
act
guidelin
three
studi
period
defin
accord
time
introduct
vaccin
dalla
prepcv
era
januari
decemb
era
januari
decemb
era
januari
june
pneumococc
isol
serotyp
capsular
swell
method
use
commerci
avail
rabbit
antipneumococc
antisera
staten
serum
institut
copenhagen
denmark
pneumococc
strain
react
pool
antisera
classifi
nontyp
select
nontyp
isol
analyz
multilocu
sequenc
type
mlst
serotyp
use
antipneumococc
antisera
base
serotyp
mlst
databas
antimicrobi
suscept
inform
obtain
cmcd
microbiolog
laboratori
use
standard
breakpoint
establish
clinic
laboratori
standard
institut
januari
clinic
laboratori
standard
institut
publish
new
nonmening
breakpoint
parenter
penicillin
therapi
penicillin
cefotaxim
breakpoint
use
studi
breakpoint
isol
locat
mening
breakpoint
suscept
penicillin
cefotaxim
perform
epsilometr
test
start
antibiot
suscept
determin
microstrep
microtit
method
dade
microscan
inc
west
sacramento
california
microbroth
dilut
method
use
muellerhinton
media
lyse
hors
blood
genet
identif
nontyp
serotyp
determin
mlst
multilocu
sequenc
type
analysi
carri
accord
previous
publish
method
intern
fragment
housekeep
gene
aro
gdh
gki
recp
spi
xpt
ddl
amplifi
polymeras
chain
reaction
pcr
chromosom
dna
obtain
pneumonia
isol
amplifi
pcr
gene
product
purifi
use
qiagen
qiaquick
pcr
purif
kit
qiagen
inc
valencia
california
sequenc
direct
use
abi
big
dye
termin
sequenc
appli
biosystem
inc
foster
citi
california
analyz
abi
capillari
instrument
univers
texa
southwestern
medic
school
mcdermott
center
sequenc
core
facil
allel
sequenc
type
assign
made
use
mlst
web
site
http
spneumoniaemlstnet
allel
alreadi
present
pneumococc
mlst
databas
verifi
resequenc
gene
fragment
strand
polymeras
chain
reactionbas
method
use
identif
virus
multicod
respiratori
viru
panel
eragen
bioscienc
inc
madison
wisconsin
test
use
februari
influenza
influenza
b
respiratori
syncyti
viru
rsv
parainfluenza
viru
adenoviru
human
metapneumoviru
rhinoviru
panel
chang
xtag
respiratori
viral
panel
luminex
molecular
diagnost
austin
texa
detect
follow
virus
subtyp
influenza
influenza
subtyp
influenza
subtyp
influenza
b
rsv
human
metapneumoviru
rhinoviru
adenoviru
septemb
xtag
rvp
replac
filmarray
respiratori
panel
idaho
technolog
salt
lake
citi
utah
test
abl
identifi
virus
adenoviru
coronaviru
coronaviru
coronaviru
coronaviru
human
metapneumoviru
rhinovirusenteroviru
influenza
influenza
influenza
influenza
influenza
b
parainfluenza
parainfluenza
parainfluenza
parainfluenza
rsv
sever
atyp
bacteria
bordetella
pertussi
chlamydophila
pneumonia
mycoplasma
pneumonia
purpos
analysi
serotyp
includ
either
pcv
vaccin
group
classifi
group
nonvaccin
serotyp
group
nontyp
group
nonvaccin
serotyp
group
repres
serotyp
contain
nontyp
group
includ
bacteri
isol
typeabl
either
capsular
swell
method
mlst
descript
analys
perform
use
median
rang
frequenc
distribut
percentag
incid
ipd
calcul
year
use
sum
hospit
emerg
center
patient
identifi
uniqu
medic
record
number
denomin
ztest
use
compar
rate
signific
level
test
trend
test
trend
analysi
use
test
chang
serotyp
antibiot
suscept
pattern
time
data
stratifi
vaccin
serotyp
nonvaccin
serotyp
invas
diseas
antimicrobi
suscept
pattern
determin
strain
associ
serotyp
type
ill
determin
calcul
odd
ratio
confid
interv
sa
softwar
sa
institut
inc
cari
north
carolina
use
statist
analys
studi
approv
institut
review
board
univers
texa
southwestern
medic
center
dalla
cmcd
studi
requir
contact
patient
famili
ident
patient
reveal
inform
consent
waiv
accord
institut
review
board
regul
identifi
male
femal
ipd
case
cmcd
januari
june
tabl
case
recurr
ipd
studi
subject
invas
diseas
caus
differ
serotyp
patient
femal
patient
syndrom
chronic
lung
diseas
present
bacteremia
serotyp
correspond
includ
analysi
singl
vaccin
serotyp
median
age
patient
month
rang
year
percentag
ipd
case
children
younger
month
decreas
consist
studi
time
period
p
studi
patient
month
age
younger
racial
distribut
show
follow
children
hispan
white
black
classifi
tabl
analysi
overal
incid
diseas
show
signific
decreas
ipd
incid
rate
p
figur
analysi
perform
studi
period
differ
diseas
incid
era
era
reach
statist
signific
p
regard
distribut
serotyp
serotyp
nonvaccin
serotyp
continu
import
caus
ipd
era
figur
princip
ill
observ
studi
follow
isol
bacteremia
pneumonia
mening
analysi
ipd
site
infect
studi
period
show
signific
variat
except
pneumonia
isol
bacteremia
case
pneumonia
era
compar
era
p
opposit
effect
observ
case
isol
bacteremia
increas
era
p
pneumococc
isol
patient
includ
studi
avail
serotyp
fortyseven
miss
sampl
isol
retrospect
collect
cmcd
microbiolog
laboratori
freezer
twentynin
serotyp
character
mlst
analysi
vaccin
group
studi
time
period
show
serotyp
decreas
pcv
era
continu
caus
ipd
era
era
case
ipd
caus
isol
serotyp
common
isol
group
follow
serotyp
f
v
patient
comorbid
repres
case
patient
without
known
underli
medic
condit
patient
younger
month
age
time
present
serotyp
common
vaccin
serotyp
isol
introduct
howev
analysi
individu
frequenc
vaccin
serotyp
era
show
signific
chang
note
serotyp
distribut
progress
reduct
frequenc
isol
common
serotyp
identifi
n
n
n
n
n
resist
pattern
isol
penicillin
cefotaxim
studi
time
period
shown
tabl
two
differ
breakpoint
includ
isol
locat
breakpoint
mening
breakpoint
penicillin
resist
interpret
mening
breakpoint
significantli
decreas
prepcv
era
era
p
result
contrast
pattern
resist
describ
isol
locat
breakpoint
resist
penicillin
accord
breakpoint
increas
significantli
prepcv
era
era
p
cefotaxim
suscept
show
signific
chang
prepcv
era
era
either
breakpoint
three
hundr
twenti
studi
patient
document
comorbid
common
group
comorbid
includ
follow
malign
histori
prematur
genet
disord
renal
diseas
asthma
inform
analyz
studi
period
statist
signific
variat
note
within
abovement
group
number
patient
sickl
cell
anemia
develop
ipd
studi
decreas
prepcv
era
era
p
major
patient
comorbid
develop
infect
caus
serotyp
includ
compar
era
interest
note
phenomenon
serotyp
replac
evid
subgroup
patient
comorbid
nonvaccin
serotyp
caus
case
ipd
compar
rest
cohort
p
widespread
use
viral
respiratori
panel
introduc
hospit
patient
test
viral
coinfect
posit
result
era
viral
test
result
return
posit
overal
percentag
patient
ipd
diagnosi
viral
coinfect
common
respiratori
virus
isol
rhinovirusenteroviru
rsv
rhinoviru
studi
provid
epidemiolog
descript
ipd
dalla
texa
use
continu
epidemiolog
surveil
infant
children
hospit
cmcd
implement
pcv
vaccin
data
immunogen
vaccin
obtain
sever
noninferior
studi
use
comparison
describ
literatur
even
singl
dose
abl
elicit
antibodi
respons
respons
presum
higher
given
immunolog
prime
studi
kinet
immun
respons
pcv
vaccin
shown
compar
antibodi
persist
common
serotyp
case
combin
immun
addit
children
previou
immun
higher
antibodi
respons
addit
serotyp
compar
patient
vaccin
alon
interest
note
vitro
crossreact
pneumonia
serotyp
necessarili
indic
clinic
protect
exampl
antibodi
produc
immun
produc
limit
crossprotect
immun
serotyp
function
analysi
antibodi
product
regard
show
vaccin
could
provid
enhanc
protect
serotyp
includ
vaccin
certain
serotyp
compar
data
provid
inform
persist
serotyp
era
frequent
serotyp
popul
f
find
contrast
recent
report
ipd
surveil
data
howev
data
similar
find
loughlin
et
al
regard
pcv
serotyp
caus
colon
describ
serotyp
persist
low
preval
popul
follow
order
frequenc
comparison
trend
ipd
introduct
vaccin
must
done
cautious
vaccin
uptak
differ
pcv
new
vaccin
introduct
took
sever
year
reach
vaccin
uptak
rate
addit
soon
licens
sever
public
rais
attent
phenomenon
serotyp
replac
data
suggest
distribut
pneumonia
serotyp
commun
evolv
independ
vaccin
point
import
natur
variat
serotyp
distribut
unrel
vaccin
abil
certain
serotyp
fill
new
ecolog
nich
natur
trend
pneumococc
serotyp
colon
effect
antibiot
use
also
consid
observ
studi
provid
avail
data
regard
serotyp
replac
import
consid
possibl
methodolog
issu
ecolog
sampl
bia
could
affect
surveil
system
use
studi
time
chang
laboratori
method
use
clinic
practic
epidemiolog
report
tool
potenti
influenc
observ
chang
ipd
incid
introduct
nonvaccin
serotyp
commonli
isol
pneumococc
pneumonia
empyema
children
franc
follow
serotyp
common
replac
serotyp
report
literatur
sinc
introduc
likewis
serotyp
common
vaccin
serotyp
isol
era
studi
era
alreadi
show
progress
reduct
frequenc
isol
zuccotti
et
al
report
frequent
serotyp
caus
ipd
itali
introduct
serotyp
also
report
caus
ipd
unit
state
studi
frequenc
isol
reach
nonvaccin
serotyp
era
epidemiolog
data
franc
suggest
strong
impact
pediatr
communityacquir
pneumonia
case
lindstrand
et
al
show
vaccin
led
signific
decreas
pneumonia
case
children
year
age
younger
data
support
find
highest
impact
pcv
seen
overal
incid
reduct
pneumonia
case
ipd
age
group
investig
houston
also
report
reduct
serotyp
caus
chronic
sinus
introduct
introduct
pcv
vaccin
evid
geograph
variat
incid
vaccin
serotyp
caus
ipd
unit
state
vaccin
introduct
magnitud
reduct
vaccinerel
ipd
due
serotyp
consist
across
site
increas
incid
ipd
caus
nonvaccin
serotyp
describ
variabl
common
serotyp
vaccin
introduct
popul
kaplan
et
al
report
common
serotyp
caus
ipd
de
st
mauric
et
al
report
similar
data
kaplan
group
regard
era
surveil
tennesse
area
common
serotyp
caus
ipd
popul
data
suggest
variat
serotyp
replac
phenomena
accord
geograph
locat
within
unit
state
interest
note
data
nation
immun
survey
center
diseas
control
prevent
show
follow
averag
estim
vaccin
coverag
pcv
vaccin
era
dalla
houston
texa
tennesse
anoth
import
aspect
pcv
surveil
includ
analysi
antimicrobi
resist
strain
caus
ipd
present
studi
find
use
mening
breakpoint
show
signific
reduct
penicillin
resist
prepcv
era
era
inform
consist
data
report
iroh
tam
et
al
show
overal
decreas
antibiot
resist
among
bacteri
isol
boston
area
hand
olart
et
al
found
penicillin
ceftriaxon
minimum
inhibitori
concentr
similar
pre
postpcv
era
sever
studi
report
effect
continu
document
ipd
case
children
underli
medic
condit
data
show
common
comorbid
list
includ
follow
malign
histori
prematur
chronic
lung
diseas
asthma
import
consid
although
differ
ipd
incid
studi
period
reach
statist
signific
case
ipd
era
common
patient
comorbid
consid
phenomena
indirect
indic
vaccin
effect
likewis
case
ipd
patient
sickl
cell
anemia
trend
cohort
like
consequ
pcv
vaccin
enforc
popul
introduct
new
viral
detect
technolog
prompt
analysi
viral
coinfect
patient
ipd
databas
show
patient
posit
viral
studi
rhinoviru
rsv
rhinovirusenteroviru
common
respiratori
viru
panel
use
present
studi
unabl
separ
human
rhinoviru
enteroviru
interact
rhinoviru
pneumonia
describ
human
cell
cultur
notabl
rhinoviru
seem
stimul
pneumonia
adhes
airway
epitheli
cell
clinic
studi
design
analyz
clinic
signific
isol
rhinoviru
patient
ipd
need
studi
limit
approxim
pneumococc
isol
avail
type
found
nontyp
sampl
belong
prepcv
era
began
prospect
collect
sampl
cmcd
microbiolog
laboratori
late
addit
mlst
avail
start
howev
isol
classifi
nontyp
period
studi
base
result
singl
tertiari
referr
center
henc
find
may
generaliz
area
countri
children
medic
center
dalla
major
referr
center
area
cover
pediatr
popul
dalla
area
howev
medic
center
includ
studi
incid
ipd
could
overestim
underestim
final
although
could
associ
vaccin
statu
individu
develop
ipd
point
averag
pcv
vaccin
rate
slightli
lower
dalla
area
compar
area
surveil
countri
find
could
potenti
contribut
differ
contain
studi
comparison
report
find
show
overal
reduct
ipd
introduct
dalla
area
penicillin
resist
among
bacteri
isol
occurr
ipd
caus
serotyp
decreas
well
interestingli
document
persist
serotyp
era
group
signific
reduct
ipd
correspond
children
younger
month
highest
impact
clinic
syndrom
seen
pneumonia
group
patient
comorbid
repres
signific
percentag
patient
ipd
addit
concern
geograph
variat
serotyp
replac
phenomena
aris
present
studi
continu
care
monitor
nation
intern
populationbas
ipd
surveil
necessari
determin
longterm
impact
group
emerg
serotyp
includ
persist
serotyp
chang
antimicrobi
suscept
possibl
geograph
differ
serotyp
distribut
address
futur
studi
